Literature DB >> 4958052

On the specificity of autoantibodies present in colon cancer patients.

S von Kleist, P Burtin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 4958052      PMCID： PMC1423742     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  15 in total

1.  CARCINOMA OF THE COLON IN ULCERATIVE COLITIS.

Authors:  M B GOLDGRABER; J B KIRSNER
Journal:  Cancer       Date:  1964-05       Impact factor: 6.860

2.  [INDUCTION OF METASTASES BY TREATMENT WITH CARCINOSTATIC AGENTS. II. DEPRESSION OF HOST RESISTANCE AND ANTIBODY PRODUCTION].

Authors:  T KONDO; H ICHIHASHI
Journal:  Gan       Date:  1964-10

3.  FLUORESCENT ANTIBODIES TO HUMAN CANCER-SPECIFIC DNA AND NUCLEAR PROTEINS.

Authors:  S PEREZ-CUADRADO; G J RACE; S HABERMAN
Journal:  Cancer       Date:  1965-02       Impact factor: 6.860

4.  Studies in tumor autoimmunity.

Authors:  J W FINNEY; E H BYERS; R H WILSON
Journal:  Cancer Res       Date:  1960-04       Impact factor: 12.701

5.  Carcinoma and ulcerative colitis, a clinical-pathologic study. I. Cancer deaths.

Authors:  M B GOLDGRABER; E M HUMPHREYS; J B KIRSNER; W L PALMER
Journal:  Gastroenterology       Date:  1958-05       Impact factor: 22.682

6.  Specific tumor antigens.

Authors:  L A ZILBER
Journal:  Adv Cancer Res       Date:  1958       Impact factor: 6.242

7.  Studies of normal and malignant tissue antigens.

Authors:  N R ROSE; S SHULMAN; E WITEBSKY
Journal:  Cancer Res       Date:  1956-10       Impact factor: 12.701

8.  The localization of antilymphosarcoma antibodies in the Murphy lymphosarcoma of the rat.

Authors:  L KORNGOLD; D PRESSMAN
Journal:  Cancer Res       Date:  1954-02       Impact factor: 12.701

9.  [Immunologic study of human breast epitheliomas].

Authors:  F Loisillier; D Buffe; K B Tan; P Burtin; P Grabar
Journal:  Ann Inst Pasteur (Paris)       Date:  1965-07

10.  ISOANTIBODIES TO HUMAN CANCER CELLS IN CANCER PATIENTS FOLLOWING CANCER HOMOTRANSPLANTS.

Authors:  T ITOH; C M SOUTHAM
Journal:  J Immunol       Date:  1964-12       Impact factor: 5.422
View more
  9 in total

1.  [Carcinofetal antigens. III. Further carcinofetal antigens (author's transl)].

Authors:  R Lamerz; A Fateh-Moghadam
Journal:  Klin Wochenschr       Date:  1975-05-01

Review 2.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 3.  Carcinoembryonic antigen (CEA).

Authors:  P W Dykes; J King
Journal:  Gut       Date:  1972-12       Impact factor: 23.059

4.  Autoimmune responses to human tumour antigens.

Authors:  M Hodkinson; G Taylor
Journal:  Br J Cancer       Date:  1969-09       Impact factor: 7.640

Review 5.  Foetal antigens and their role in the diagnosis and clinical management of human neoplasms: a review.

Authors:  D J Laurence; A M Neville
Journal:  Br J Cancer       Date:  1972-10       Impact factor: 7.640

6.  Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.

Authors:  Hemanth K Potluri; Tun Lee Ng; Michael A Newton; Jin Zhang; Christopher A Maher; Peter S Nelson; Douglas G McNeel
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

7.  Physicochemical studies of the carcinoembryonic antigens of the human digestive system.

Authors:  J Krupey; P Gold; S O Freedman
Journal:  J Exp Med       Date:  1968-09-01       Impact factor: 14.307

8.  Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract?

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

9.  Elevated plasma YKL-40 level is found in the dogs with cancer and is related to poor prognosis.

Authors:  Kai Chung Cheng; Jih Jong Lee; Shang Lin Wang; Chun Yu Lin; Ching Tien Tseng; Chen Si Lin; Albert Taiching Liao
Journal:  J Vet Sci       Date:  2019-09       Impact factor: 1.672
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.